Connect with us

Hi, what are you looking for?

Politics

Senate committee advances nomination of Dr Oz to run Centers for Medicare and Medicaid Services

The Senate Committee on Finance voted along party lines Tuesday afternoon to advance Dr. Mehmet Oz, President Donald Trump’s pick to lead the Centers for Medicare and Medicaid Services, to a full confirmation vote.

The party-line vote, which saw 14 GOP senators vote in favor of Oz’s nomination and 13 Democrats vote against it, follows two hearings by the Senate Finance Committee that probed Oz over his plans for the federal healthcare programs, his views on abortion, potential conflicts of interest in the healthcare industry and more.

‘Dr. Oz has years of experience as an acclaimed physician and public health advocate. His background makes him uniquely qualified for this role, and there is no doubt that he will work tirelessly to deliver much-needed change at CMS,’ Sen. Mike Crapo, R-Idaho, the chairman of the committee, said Tuesday.

Oz graduated from Harvard University and received medical and business degrees from the University of Pennsylvania. He is a former heart surgeon who saw his fame rise through his appearances on daytime TV and 13 seasons of ‘The Dr Oz Show.’

Oz later transitioned into politics, launching an unsuccessful bid for Pennsylvania’s open Senate seat in 2022. He ultimately lost to John Fetterman, then the state’s lieutenant governor.

If confirmed by the full Senate, Oz would be in charge of nearly $1.5 trillion in federal healthcare spending. Medicare, a federal healthcare program for seniors aged 65 and up, currently provides coverage for about 65 million Americans, according to the Center for Medicare Advocacy. Medicaid, which assists people with low incomes, covers roughly 72 million Americans, according to Medicaid.gov.

Oz’s leadership would direct decisions related to how the government covers procedures, hospital stays and medication within the federal healthcare programs, as well as the reimbursement rates at which healthcare providers get paid for their services.

Earlier this month, Trump’s pick to lead the NIH and FDA, Dr. Jay Bhattacharya and Dr. Marty Makary, respectively, were also approved in committee and are awaiting full confirmation votes in the Senate scheduled for later Tuesday. It is unclear when Oz’s full Senate vote will take place.

Around the same time that Bhattacharya and Makary won committee approval, Trump withdrew his nomination of former Florida Rep. David Weldon to run the CDC, over fears he did not have the GOP support to clear full confirmation. On Monday, the Trump administration named Susan Monarez, acting director of the CDC, as its new nominee.

This post appeared first on FOX NEWS
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

    Fill Out & Get More Relevant News


    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    You May Also Like

    Business

    Nvidia CEO Jensen Huang on Thursday walked back comments he made in January, when he cast doubt on whether useful quantum computers would hit the...

    Politics

    President Donald Trump revoked the security clearances of Joe Biden, Hillary Clinton, Kamala Harris, Liz Cheney and several other opponents who either severely criticized...

    Stocks

    Seeing that the earnings slate is light, this week we focus on certain stocks to watch during uncertain times. If you are jittery and...

    Politics

    Dozens of Tesla vehicles were damaged at a dealership in Ontario, Canada, Hamilton Police Service (HPS) confirmed to Fox News Digital. Authorities said that...

    Disclaimer: EasyProfitResearch.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 EasyProfitResearch.com | All Rights Reserved